| First agent specifically approved for use (in combination with 5-FU/LV) in this setting |
| Added to 5-FU/LV, nal-IRI significantly improved survival outcomes vs. 5-FU/LV alone |
| Most common grade 3–4 adverse events included neutropenia and diarrhoea |
| Real-world data confirm effectiveness and safety of nal-IRI + 5-FU/LV in clinical practice |
| Dose modifications for adverse events do not appear to adversely affect survival outcomes |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.